Portal de Periódicos da CAPES

Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3Kα inhibitors

2019; American Association for the Advancement of Science; Volume: 366; Issue: 6466 Linguagem: Inglês

10.1126/science.aaw9032

1095-9203

Neil Vasan, Pedram Razavi, Jared L. Johnson, Hong Shao, Hardik Shah, Alesia Antoine, Erik Ladewig, Alexander N. Gorelick, Ting-Yu Lin, Eneda Toska, Guotai Xu, Abiha Kazmi, Matthew T. Chang, Barry S. Taylor, Maura N. Dickler, Komal Jhaveri, Sarat Chandarlapaty, Raúl Rabadán, Ed Reznik, Melissa Smith, Robert Sebra, Frauke Schimmöller, Timothy R. Wilson, Lori S. Friedman, Lewis C. Cantley, Maurizio Scaltriti, José Baselga,

Chronic Lymphocytic Leukemia Research

Seeing double can be a good thing Many human breast cancers harbor activating mutations in PIK3CA , the gene coding for the catalytic subunit of phosphoinositide 3-kinase (PI3K). Clinical trials are underway to evaluate the efficacy of PI3K inhibitors in cancer patients. Vasan et al. found unexpectedly that a subset of breast cancers harbor not one—but two— PIK3CA mutations, and the mutations occur on the same allele (see the Perspective by Toker). In model systems, the double mutations hyperactivate PI3K signaling and enhance tumor growth. Preliminary analysis of clinical trial data suggests that breast cancers with double mutations are more responsive to PI3K inhibitors than those with a single mutation. PIK3CA mutational status could help identify the breast cancer patients most likely to benefit from these drugs. Science , this issue p. 714 ; see also p. 685